

## Review on RP-HPLC Method Development and Validation of Cefixime and Azithromycinin Pharmaceutical Dosage Form

Umesh G R, Dr Arnika Das, Dr Paul Richards M, Suman V R, R Suresh Babu

Department of pharmaceutical Analysis, Aditya Bangalore Institute of Pharmacy Education and Research, Affiliated to Rajiv Gandhi University of Health Sciences and Government of Karnataka Kogilu, Yelahanka, Bangalore-64 Karnataka, India

Received: 2025-7-20

Revised: 2025-8-12

Accepted: 2025-8-16


### ABSTRACT

A variety of simple, precise, and robust RP-HPLC methods have been developed and validated for the simultaneous estimation of azithromycin and cefixime, both in bulk and in pharmaceutical dosage forms. Across different studies, methods using different columns (C8 and C18) and mobile phase compositions (phosphate buffers with acetonitrile or methanol) have shown excellent linearity, accuracy, precision, and specificity, complying with ICH guidelines. Stress testing confirmed the stability-indicating capability of the developed methods, with minimal interference from excipients. The methods demonstrated strong recovery rates, low LOD and LOQ values, and rapid analysis times, making them reliable for routine quality control and stability studies. Overall, these developed HPLC methods offer a cost-effective, sensitive, and reproducible approach for the simultaneous analysis of azithromycin and cefixime in pharmaceutical formulation.


**Keywords:** RP-HPLC, Azithromycin, Cefixime, Linearity.

### I. INTRODUCTION TO DRUG PROFILE

Cefixime (CFI) is an orally active third-generation cephalosporin antibiotic ( $C_{16}H_{15}N_5O_7S_2 \cdot 3H_2O$ , molecular weight 507.50 g/mol) that inhibits bacterial cell wall synthesis. It is widely used to treat respiratory tract infections, urinary tract infections, sinusitis, otitis media, and *Helicobacter pylori* infections.



Azithromycin (AZT), a macrolide antibiotic ([9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate]), blocks bacterial protein synthesis by binding to the 50S ribosomal subunit. It is effective against respiratory infections, cystic fibrosis, COPD-related inflammation, malaria (with other antimalarials), typhoid fever, and *Neisseria gonorrhoeae* infections.



Both drugs are official in the **Indian Pharmacopoeia (2010)**. While various analytical methods like **HPLC**, **LC-MS/MS**, **micellar chromatography**, **UV spectrophotometry**, and **HPTLC** have been reported for individual estimation, no method has been documented for their simultaneous analysis in pharmaceutical formulations.

## II. Summary of Analytical Methods

### Reported analytical methods for Cefixime and Azithromycin

SLno no	Drug	Method	Brief description
1	Cefixime and Azithromycin	RP-HPLC	<b>Column:</b> Phenomenex C18 column (250 x 4.6mm, 5 $\mu$ m) <b>Mobile phase:</b> 0.02M Potassium dihydrogen phosphate (KH <sub>2</sub> PO <sub>4</sub> ): Acetonitrile in the ratio of 65:35 (v/v) <b>Detected Wavelength:</b> 227 nm <b>Flow rate:</b> 1 ml/min <b>Retention time:</b> 6.94 & 5.22 min <b>Linearity range:</b> 40-60 & 50-70 $\mu$ g/ml
2	Cefixime	RP-HPLC	<b>Column:</b> C18 (zodiac company) <b>Mobile phase:</b> Methanol:Acetonitrile (30:70) <b>Detected Wavelength:</b> 243 nm <b>Flow rate:</b> 1.1 ml/min <b>Run time:</b> 2.9mins <b>Linearity range:</b> 100-600 $\mu$ g/ml
3	Azithromycin and Cefixime	RP-HPLC	<b>Column:</b> Agilent Zorbax C8, 5 $\mu$ column having 150 x 4.6mm <b>Mobile phase:</b> 0.1M Dipotassium Hydrogen Phosphate Buffer : methanol (60:40 %v/v pH: 8.0 adjusted with Ortho phosphoric acid <b>Detected Wavelength:</b> 230 nm <b>Flow rate:</b> 1.1 ml/min <b>Retention time:</b> 2.7 & 4.6 min <b>Linearity range:</b> 250-750 $\mu$ g/mL and 200-600 $\mu$ g/mL
4	Cefixime and Azithromycin	RP-HPLC	<b>Column:</b> Inertsil -ODS C18(250 x 4.6 mm, 5 $\mu$ ) <b>Mobile phase:</b> Methanol : Buffer (85:15) <b>Detected Wavelength:</b> 275 nm <b>Flow rate:</b> 1 ml/min <b>Retention time:</b> 2.186 & 3.968 min <b>Linearity range:</b> 20-80 $\mu$ g/ml
5	Azithromycin and Cefixime	RP-HPLC	<b>Column:</b> Supleco C18 (25cm $\times$ 4.6 mm, 5 $\mu$ m) <b>Mobile phase:</b> 80:20 Na <sub>2</sub> HPO <sub>4</sub> : Methanol <b>Detected Wavelength:</b> 273 nm <b>Flow rate:</b> 1 ml/min <b>Retention time:</b> 2.77 & 4.93 min <b>Linearity range:</b> 50-150 $\mu$ g/ml
6	Azithromycin and Cefixime	RP-HPLC	<b>Column:</b> Kromasil C18 column <b>Mobile phase:</b> Ortho Phosphoric Acid buffer and Methanol in the ratio of 70:30 v/v <b>Detected Wavelength:</b> 292 nm <b>Flow rate:</b> 1 ml/min <b>Retention time:</b> 2.8 & 3.9 min <b>Linearity range:</b> 0.5 1.5 mg/ml., 0.4-1.2 mg/ml
7	Azithromycin	RP-HPLC	<b>Column:</b> Column ODS-3 (250 mm $\times$ 4.6 mm x 5 $\mu$ m) <b>Mobile phase:</b> Methanol: Phosphate buffer (9:1, v/v) <b>Detected Wavelength:</b> 210 nm <b>Flow rate:</b> 1.2 ml/min <b>Linearity range:</b> 0.5 1.5 mg/ml., 0.4-1.2 mg/ml

### III.CONCLUSION:

Several RP-HPLC methods have been developed for the estimation of Cefixime and Azithromycin individually and simultaneously, mostly using C18 columns with different mobile phases comprising phosphate buffers combined with methanol or acetonitrile. Detection wavelengths varied between 210 nm and 292 nm, depending on the method, and flow rates ranged from 1.0 to 1.2 mL/min, ensuring efficient separations. Retention times for Cefixime and Azithromycin were generally short, between approximately 2 to 7 minutes, allowing rapid analysis. Linearity ranges covered a broad spectrum from low  $\mu\text{g/mL}$  levels (20–80  $\mu\text{g/mL}$ ) to high  $\text{mg/mL}$  levels (0.5–1.5  $\text{mg/mL}$ ), making the methods suitable for different types of pharmaceutical analyses. Overall, the methods are efficient, sensitive, and flexible, and the choice of method can be tailored based on required sensitivity, sample concentration, and analysis time.

### IV.REFERENCES :

1. Nyola N, Jeyabalan S. Simultaneous estimation of Cefixime and Azithromycin in API's and pharmaceutical dosage form by RP-HPLC. *Indo American Journal of Pharmaceutical Research*. 2013;2(12):1472-81.
2. Swathi V, Narendra D, Sandhya K, Surekha S, Devi TN. Method development and validation of Cefixime by using RP-HPLC in pharmaceutical formulations. *International Journal of Research in AYUSH and Pharmaceutical Sciences*. 2023 Apr 22:4-7.
3. Ramesh M, Durga MK, Sravani A, Snehalatha T, Thimmareddy D. A new stability indicating validated RP-HPLC method for the simultaneous estimation of azithromycin and cefixime in bulk and pharmaceutical dosage forms. *Asian Journal of Research in Chemistry*. 2012 Aug 1;5(8):XI.
4. Nagaraju K. Development and validation of new RP-HPLC method for simultaneous estimation of drug Cefixime and Azithromycin in tablet dosage form. *Indian Journal of Research in Pharmacy and Biotechnology*. 2016 Sep 1;4(5):223.
5. Nagaraju K, Chowdary YA. Analytical Method Development and Validation for The Simultaneous Estimation of Azithromycin and Cefixime by Rp-Hplc Method in Bulk and Pharmaceutical Formulations. *International Journal of Research in Science and Technology*. 2018;4.
6. Gundala U, Bonagiri C, Nayakanti D. Simultaneous estimation of azithromycin and cefixime in bulk and pharmaceutical formulation by Reverse Phase High Performance Liquid Chromatography (RP-HPLC). *World Journal of Pharmaceutical Research*. 2014 Mar 12;3.
7. Al-Hakkani MF. A rapid, developed and validated RP-HPLC method for determination of azithromycin. *SN Applied Sciences*. 2019 Mar;1(3):222.
8. Suhagia BN, Shah SA, Rathod IS, Patel HM, Doshi KR. Determination of azithromycin in pharmaceutical dosage forms by spectrophotometric method. *Indian journal of pharmaceutical sciences*. 2006 Mar 1;68(2).
9. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R, Yerramilli A. Sensitive and selective liquid chromatography–tandem mass spectrometry method for the quantification of azithromycin in human plasma. *Analytica Chimica Acta*. 2005 Nov 30;553(1-2):1-8.
10. Khedr A, Sheha M. Quantitative thin-layer chromatographic method of analysis of azithromycin in pure and capsule forms. *Journal of chromatographic science*. 2003 Jan 1;41(1):10-6.
11. Yanamandra R, Chaudhary A, Bandaru SR, Patro B, Murthy YL, Ramaiah PA, Sastry CS. UPLC method for simultaneous separation and estimation of secnidazole, fluconazole and azithromycin in pharmaceutical dosage forms. *Journal of Chemistry*. 2010;7:S363-71.
12. Ghari T, Kobarfard F, Mortazavi SA. Development of a Simple RP-HPLC-UV Method for Determination of Azithromycin in Bulk and Pharmaceutical Dosage forms as an Alternative to the USP Method. *Iranian journal of pharmaceutical research: IJPR*. 2013;12(Suppl):57.
13. Breier AR, Garcia CV, Oppe TP, Steppe M, Schapoval EE. Microbiological assay for azithromycin in pharmaceutical formulations. *Journal of pharmaceutical and biomedical analysis*. 2002 Jul 31;29(5):957-61.
14. Zeng A, Liu X, Zhang S, Zheng Y, Huang P, Du K, Fu Q. Determination of azithromycin in raw materials and pharmaceutical formulations by HPLC coupled with an evaporative light scattering detector. *asian journal of pharmaceutical sciences*. 2014 Apr 1;9(2):107-16.
15. Taninaka C, Ohtani H, Hanada E, Kotaki H, Sato H, Iga T. Determination of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by high-performance liquid chromatography with amperometric detection. *Journal of Chromatography B: Biomedical Sciences and Applications*. 2000 Feb 11;738(2):405-11.
16. Torano JS, Guchelaar HJ. Quantitative determination of the macrolide antibiotics erythromycin, roxithromycin, azithromycin and clarithromycin in human serum by high-performance liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence detection. *Journal of Chromatography B: Biomedical Sciences and Applications*. 1998 Dec 11;720(1-2):89-97.
17. Bahrami G, Mohammadi B. A new on-line, in-tube pre-column derivatization technique for high performance liquid chromatographic determination of azithromycin in human serum. *Journal of chromatography B*. 2006 Jan 18;830(2):355-8.




18. Ferrara A, Dos Santos C, Cimbro M, Grassi GG. Comparative antimicrobial activity and post-antibiotic effect of azithromycin, clarithromycin and roxithromycin against some respiratory pathogens. *International journal of antimicrobial agents*. 1996 Aug 1;7(3):181-6.
19. Block SL, Arrieta A, Seibel M, McLinn S, Eppes S, Murphy MJ. Single-dose (30 mg/kg) azithromycin compared with 10-day amoxicillin/clavulanate for the treatment of uncomplicated acute otitis media: a double-blind, placebo-controlled, randomized clinical trial. *Current therapeutic research*. 2003 Jan 1;64:30-42.
20. Raja MS, Shan SH, Moorthy S, Perumal P. RP-HPLC method development and validation for the simultaneous estimation of azithromycin and ambroxol hydrochloride in tablets. *International Journal of Pharm Tech Research*. 2010;2(1):36-9.
21. Eric-Jovanovic S, Agbaba D, Zivanov-Stakic D, Vladimirov S. HPTLC determination of ceftriaxone, cefixime and cefotaxime in dosage forms. *Journal of pharmaceutical and biomedical analysis*. 1998 Dec 1;18(4-5):893-8.
22. Meng F, Chen X, Zeng Y, Zhong D. Sensitive liquid chromatography–tandem mass spectrometry method for the determination of cefixime in human plasma: Application to a pharmacokinetic study. *Journal of Chromatography B*. 2005 May 25;819(2):277-82.
23. Honda S, Taga A, Kakehi K, Koda S, Okamoto Y. Determination of cefixime and its metabolites by high-performance capillary electrophoresis. *Journal of Chromatography A*. 1992 Jan 31;590(2):364-8.



How to cite this article:

Umesh G R et al. *Ijsrm.Human*, 2025; Vol. 28 (8): 1-5

Conflict of Interest Statement: All authors have nothing else to disclose.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

	<p>Author Name: Umesh G R</p> <p>Author Affiliation: M Pharm Student</p> <p>Author Address/Institute Address: Aditya Bangalore Institute of Pharmacy Education and Research</p>
	<p>Author Name: Dr Arnika Das</p> <p>Author Affiliation: Assistant Professor, ABIPER, RGUHS, Kogilu Main Rd, Yelahanka, Bengaluru, Karnataka 560064</p> <p>Author Address/Institute Address: Aditya Bangalore Institute of Pharmacy Education and Research</p>
	<p>Author Name: Dr Paul Richards M</p> <p>Author Affiliation: Professor, ABIPER, RGUHS, Kogilu Main Rd, Yelahanka, Bengaluru, Karnataka 560064</p> <p>Author Address/Institute Address: Aditya Bangalore Institute of Pharmacy Education and Research</p>

	<p>Author Name: Suman V R</p> <p>Author Affiliation: M Pharm Student</p> <p>Author Address/Institute Address: Aditya Bangalore Institute of Pharmacy Education and Research</p>
	<p>Author Name: R Suresh Babu</p> <p>Author Affiliation: M Pharm Student</p> <p>Author Address/Institute Address: Aditya Bangalore Institute of Pharmacy Education and Research</p>